[
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
    "title": "Kvartalsrapport Q1 2026",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/aef628bb051762f152807cda4a5c133c9",
    "date": "2026-05-27",
    "period": "2026-q1",
    "form_type": "interim-report",
    "report_key": "2026:q1",
    "filename": "SynAct_Pharma_Q1_2026_Delarsrapport.pdf",
    "text_chars": 89833,
    "sha256": "2e857f4d02c1d3a9483800a2d9b775729fff9fed9ee497f0973f7e87322e4b97",
    "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
    "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
    "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
        "chars": 89833
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2025",
    "title": "Årsredovisning 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a459e70f487d42df785c6bb5c7faf489a",
    "date": "2026-04-15",
    "period": "2025-annual",
    "form_type": "annual-report",
    "report_key": "2025:annual",
    "filename": "SynAct_Pharma_AB_Arsredovisning_2025.pdf",
    "text_chars": 285170,
    "sha256": "990b1b3dd10a421ca68244074ce2aef48d441b54944c9d912f57803bcc3c6e91",
    "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2025",
    "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2025",
    "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
        "chars": 179057
      },
      {
        "number": 2,
        "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
        "chars": 106111
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
    "title": "Kvartalsrapport Q4 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/aacfe3c91766da9d853ef2d782fed5c73",
    "date": "2026-02-18",
    "period": "2025-q4",
    "form_type": "year-end-report",
    "report_key": "2025:q4",
    "filename": "SynAct_Pharma_Q4_2025_Delarsrapport.pdf",
    "text_chars": 90669,
    "sha256": "2b486bd51ce23ff281f5af5b5a73213867292be738267531cfc10cf2bf1f5de1",
    "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
    "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
    "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
        "chars": 90669
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
    "title": "Kvartalsrapport Q3 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a9aa6754168c9d211bb79cf0bd9ea3c4e",
    "date": "2025-10-30",
    "period": "2025-q3",
    "form_type": "interim-report",
    "report_key": "2025:q3",
    "filename": "SynAct_Pharma_Q3_2025_Delarsrapport.pdf",
    "text_chars": 89961,
    "sha256": "334a266722ca6536cd1fa365a15bbb2bae489b22f558e145500792e705e29151",
    "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
    "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
    "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
        "chars": 89961
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
    "title": "Kvartalsrapport Q2 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/abb85308bea260d076ba2c5c4f3950960",
    "date": "2025-08-20",
    "period": "2025-q2",
    "form_type": "interim-report",
    "report_key": "2025:q2",
    "filename": "SynAct_Pharma_Q2_2025_Delarsrapport.pdf",
    "text_chars": 85186,
    "sha256": "89acc586725d0dc585547f14d032093321e136369e5576f1b9bdb89a7d394660",
    "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
    "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
    "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
        "chars": 85186
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
    "title": "Kvartalsrapport Q1 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/af03394fd18f44f9f7460b90bb573c281",
    "date": "2025-05-27",
    "period": "2025-q1",
    "form_type": "interim-report",
    "report_key": "2025:q1",
    "filename": "SynAct_Pharma_Q1_2025_Delarsrapport.pdf",
    "text_chars": 79745,
    "sha256": "f7fbf9bd26e12ccbb00005fd5f31a781c88390c9b399700675a1767f6b0fb6a2",
    "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
    "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
    "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
        "chars": 79745
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2024",
    "title": "Årsredovisning 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a55291ac91810d4e6b483d2b5b3ff628e",
    "date": "2025-04-10",
    "period": "2024-annual",
    "form_type": "annual-report",
    "report_key": "2024:annual",
    "filename": "SynAct_Pharma_AB_Arsredovisning_2024.pdf",
    "text_chars": 280555,
    "sha256": "ce15cb2f11cde6b84bb7906187c0d60655e366a6916d188b4d0af5be1d3756ed",
    "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2024",
    "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2024",
    "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
        "chars": 179972
      },
      {
        "number": 2,
        "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
        "chars": 100581
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
    "title": "Kvartalsrapport Q4 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a7244d301ff63415f15fa946cdc137082",
    "date": "2025-02-18",
    "period": "2024-q4",
    "form_type": "year-end-report",
    "report_key": "2024:q4",
    "filename": "SynAct_Pharma_Q4_2024_Delarsrapport.pdf",
    "text_chars": 77354,
    "sha256": "569b64ec4f7fc3bfe36417d573ad58a3909b9b3e69986e46c391cdd9eeb7a0fd",
    "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
    "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
    "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
        "chars": 77354
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
    "title": "Kvartalsrapport Q3 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a624caea2485d1f24373c8eeaaa8a03be",
    "date": "2024-10-30",
    "period": "2024-q3",
    "form_type": "interim-report",
    "report_key": "2024:q3",
    "filename": "SynAct_Pharma_Q3_2024_Delarsrapport.pdf",
    "text_chars": 76160,
    "sha256": "7c8a711c3a4d3d8fa874537d61836642f5675e790a2499701709ecbc2640eba7",
    "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
    "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
    "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
        "chars": 76160
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
    "title": "Kvartalsrapport Q2 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a9661055a47fa9fd0ca97f5c3119534ca",
    "date": "2024-08-20",
    "period": "2024-q2",
    "form_type": "interim-report",
    "report_key": "2024:q2",
    "filename": "SynAct_Pharma_Q2_2024_Delarsrapport.pdf",
    "text_chars": 69351,
    "sha256": "fa27f4242fb3a44034232792f64bf5f3afb3870e46a9daf45c4abca310838a00",
    "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
    "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
    "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
        "chars": 69351
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
    "title": "Kvartalsrapport Q1 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/aaf75ad2e30ba61a9470d9cf567dd8be5",
    "date": "2024-05-31",
    "period": "2024-q1",
    "form_type": "interim-report",
    "report_key": "2024:q1",
    "filename": "SynAct_Pharma_Q1_2024_Delarsrapport.pdf",
    "text_chars": 68803,
    "sha256": "913da495e5a30426e81fae77abcf35d33ce3b31cb011c79aacef0a522670f8f2",
    "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
    "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
    "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
        "chars": 68803
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2023",
    "title": "Årsredovisning 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a1ec65c58dae6cb556634909826df1f8f",
    "date": "2024-03-26",
    "period": "2023-annual",
    "form_type": "annual-report",
    "report_key": "2023:annual",
    "filename": "SynAct_Pharma_AB_Arsredovisning_2023.pdf",
    "text_chars": 293672,
    "sha256": "9b266db204f6a3f046d1e162c09a076f94e134618085bb805c9248e197fe3732",
    "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2023",
    "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2023",
    "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
        "chars": 179635
      },
      {
        "number": 2,
        "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
        "chars": 114035
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
    "title": "Kvartalsrapport Q4 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a9cf323e4ab27f6b24e4e9b52cd7e85c4",
    "date": "2024-02-23",
    "period": "2023-q4",
    "form_type": "year-end-report",
    "report_key": "2023:q4",
    "filename": "SynAct_Pharma_Q4_2023_Delarsrapport.pdf",
    "text_chars": 79563,
    "sha256": "2ab48236d6bcfe24afc35c6544ae3ec7a6b4d2926f084c562312dc86e60efd2c",
    "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
    "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
    "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
        "chars": 79563
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
    "title": "Kvartalsrapport Q3 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a2addd2988ae7f74674ece98ee7708eff",
    "date": "2023-10-24",
    "period": "2023-q3",
    "form_type": "interim-report",
    "report_key": "2023:q3",
    "filename": "SynAct_Pharma_Q3_2023_Delarsrapport.pdf",
    "text_chars": 81241,
    "sha256": "55926ab9c1a78796f8773eced3b263b36a0e3f208958fc49f33948407ae5e0f9",
    "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
    "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
    "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
        "chars": 81241
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
    "title": "Kvartalsrapport Q2 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a997d2060d116c6cafbe787ec40bc9d78",
    "date": "2023-08-04",
    "period": "2023-q2",
    "form_type": "interim-report",
    "report_key": "2023:q2",
    "filename": "SynAct_Pharma_Q2_2023_Delarsrapport.pdf",
    "text_chars": 79425,
    "sha256": "f701b6dbdd4b13f3b5dc1caa01bfe0b81692fa88b8e68849f05ab2bc51a70c1b",
    "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
    "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
    "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
        "chars": 79425
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
    "title": "Kvartalsrapport Q1 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a567fdc9793be18c6b909ff87e1934bf6",
    "date": "2023-05-05",
    "period": "2023-q1",
    "form_type": "interim-report",
    "report_key": "2023:q1",
    "filename": "SynAct_Pharma_Q1_2023_Delarsrapport.pdf",
    "text_chars": 82787,
    "sha256": "57add4595e5fa405563d3c5e30f444197bdef62aeb4b8ba1fc6cd3f6f6e78407",
    "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
    "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
    "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
        "chars": 82787
      }
    ]
  },
  {
    "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata",
    "title": "MFN bolagssida och bolagsmetadata",
    "source": "MFN",
    "source_class": "mfn",
    "source_url": "https://mfn.se/all/a/synact-pharma",
    "date": null,
    "period": null,
    "form_type": "company-page",
    "report_key": null,
    "filename": "company.txt",
    "text_chars": 12805,
    "sha256": "fa65fb735ee584ba0ad662b2a7bd9e8ff2bbbe1b0ff48d51b16b25e406fe63ec",
    "url": "/company/synact-pharma-ab/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
    "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
    "txt_url": "/company/synact-pharma-ab/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/synact-pharma-ab/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html",
        "chars": 12805
      }
    ]
  }
]